A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.

Josep María Del Campo,Michael Birrer,Craig Davis,Keiichi Fujiwara,Ashwin Gollerkeri,Martin Gore,Brett Houk,Susie Lau,Andres Poveda,Antonio González-Martín,Carolyn Muller,Kei Muro,Kristen Pierce,Mie Suzuki,Jennifer Vermette,Amit Oza

Gynecologic Oncology（2016）

引用 66|浏览52

暂无评分

摘要

•Two PI3K/mTOR inhibitors were evaluated in recurrent endometrial cancer patients.•Gedatolisib demonstrated activity in stathmin-low expressing endometrial cancers.•Appropriate biomarkers to direct gedatolisib therapy were not confirmed in the study.

查看译文

关键词

Endometrial cancer,Gedatolisib,mTOR,PI3K,Stathmin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要